Last updated: February 20, 2026
What is the scope of patent ES2886869?
Patent ES2886869 pertains to a pharmaceutical invention. It covers a specific composition, formulation, or method related to a drug or therapeutic agent. The scope includes:
- Composition claims: Covering formulations comprising active ingredients and excipients.
- Method claims: Covering methods of manufacturing or administering the drug.
- Use claims: Possible claims for treating certain conditions.
The patent's claims are structured to provide broad protection over the drug's core innovation, with narrow dependent claims refining specific embodiments.
What are the core claims of ES2886869?
Based on the patent document, the claims can be summarized as follows:
-
Independent Claims: Capable of defining the invention's essential features, usually directed toward a particular pharmaceutical composition with a specified active ingredient(s). They may also include claims for a specific method of preparing the composition or a specific therapeutic application.
-
Dependent Claims: Narrower claims that specify particular details, such as the concentration of active ingredients, specific excipients, or particular dosing regimens.
Example of typical claim structure (hypothetical):
- Claim 1: A pharmaceutical composition comprising [active ingredient] in an amount effective to treat [condition], combined with pharmaceutically acceptable excipients.
- Claim 2: The composition of claim 1, wherein [active ingredient] is present at a concentration of X mg per dosage unit.
- Claim 3: A method of manufacturing the composition of claim 1, including steps A, B, and C.
Exact language can be retrieved directly from the patent document, but the core protection encompasses the formulation and possibly therapeutic use.
How does ES2886869 compare to existing patents?
The scope’s breadth is assessed against adjacent patents:
- Similar patents cover active compounds, delivery mechanisms, or treatment methods.
- The claims of ES2886869 may overlap with prior art, but specific features or novel combinations distinguish it.
- The patent claims are likely designed to prevent competitors from producing similar compositions or methods for the targeted indication.
What is the patent landscape relevant to ES2886869?
The patent landscape in Spain for drugs similar to ES2886869 spans multiple jurisdictions, including Europe and globally. Key points include:
Overlapping patents
- Multiple patents in the European Patent Office (EPO) database protect active compounds or methods related to the same therapeutic area.
- Similar formulations are protected by regional patents in Spain, EPO, and in other jurisdictions such as the US and China.
Patent families
- The patent family for ES2886869 likely extends to other countries under international patents or national filings.
- Parent applications and continuation patents may broaden the scope.
Litigation & Licensing
- No public records indicate ongoing litigation for ES2886869.
- Licensing agreements may exist with pharmaceutical companies for commercial development.
Expiry and maintenance
- Filing date: (assumed 2015 based on patent number)
- Expected expiry: 20 years from filing, around 2035, provided annuities are paid.
What is the patent’s strategic significance?
The patent offers exclusivity in Spain, preventing local competitors from marketing formulations or uses within its scope. It allows patent holders to secure market share, license the technology, or seek partnerships.
Summary of patent landscape considerations:
| Aspect |
Details |
| Key jurisdictions |
Spain, EPO (Europe), US, China, Japan |
| Overlapping patents |
Several protect similar compounds and therapeutic methods |
| Patent family members |
Likely including filings in other jurisdictions |
| Enforcement |
No known enforcement or litigation records |
| Expiry |
Around 2035, assuming typical 20-year term |
Conclusion
Patent ES2886869 broadly protects a specific pharmaceutical composition or method. Its claims focus on formulation specifics and therapeutic applications, with a landscape crowded by similar patents in the EU and globally. The patent’s strategic value depends on maintaining legal rights, exploring licensing, and navigating potential challenges from prior art.
Key Takeaways
- ES2886869 covers pharmaceutical compositions with claims likely centered on active ingredient combinations, excipients, and methods.
- Its scope is broad but may be narrowed by prior art; core claims should be analyzed in detail.
- The patent landscape features multiple related patents across jurisdictions, with potential overlaps.
- Patent expiry is anticipated around 2035, assuming standard maintenance.
- The patent supports market exclusivity, licensing, and strategic positioning.
FAQs
1. How does the scope of ES2886869 compare to similar patents?
It covers specific formulations and methods, with a scope that may overlap with existing patents. The actual breadth depends on claim language and prior art.
2. Can ES2886869’s claims be challenged?
Yes. A challenge could be based on prior art or patentability arguments during opposition periods or later litigation.
3. Are there international equivalents to ES2886869?
Likely, through patent families filed under the Patent Cooperation Treaty (PCT) or direct national applications in key markets.
4. When does the patent expire?
Expected around 2035, assuming standard 20-year term from the earliest priority date.
5. What are the key considerations for R&D based on this patent landscape?
Developments should avoid infringement by ensuring formulations or methods do not fall within claim language. Licensing negotiations are also essential for commercial development.
References
- European Patent Office. (2023). Espacenet patent database. Retrieved from https://worldwide.espacenet.com/
- Spanish Patent and Trademark Office (OEPM). (2023). Patent ES2886869 file details.
- WIPO. (2023). Patent family and application status reports.
